Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation
NCT04234360
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
600
Enrollment
OTHER
Sponsor class
Conditions
COPD Exacerbation
Interventions
DRUG:
5 days of systemic corticotherapy (prednisone)
DRUG:
5 days of placebo
Sponsor
University Hospital, Montpellier